Open access · CC-BY
via OpenAlex
The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review
Xianzhuo Zhang, Xufei Luo, Tian Gang Liang, Ping Yue, Mengyao Li, Kefeng Liu, Daoming Zhu, Chongfei Huang, Qianling Shi, Liping Yang, Zhili Xia, Jinyu Zhao, Zelong Ma, Jianlong Li, Joseph W. Leung
Frontiers in Microbiology · 2023 · ▲ 39 citations
Abstract
Background Gut microbiome dysbiosis has been implicated in various gastrointestinal and extra-gastrointestinal diseases, but evidence on the efficacy and safety of fecal microbiota transplantation (FMT) for therapeutic indications remains unclear. Methods The gutMDisorder database was used to summarize the associations between gut microbiome dysbiosis and diseases. We performed an umbrella review of published meta-analyses to determine the evidence synthesis on the efficacy and safety of FMT in treating various diseases. Our study was registered in PROSPERO (CRD42022301226). Results Gut microbiome dysbiosis was associated with 117 gastrointestinal and extra-gastrointestinal. Colorectal cancer was associated with 92 dysbiosis. Dysbiosis involving Firmicutes (phylum) was associated with 34 diseases. We identified 62 published meta-analyses of FMT. FMT was found to be effective for 13 diseases, with a 95.56% cure rate (95% CI: 93.88–97.05%) for recurrent Chloridoids difficile infection (rCDI). Evidence was high quality for rCDI and moderate to high quality for ulcerative colitis and Crohn’s disease but low to very low quality for other diseases. Conclusion Gut microbiome dysbiosis may be implicated in numerous diseases. Substantial evidence suggests FMT improves clinical outcomes for certain indications, but evidence quality varies greatly depending on the specific indication, route of administration, frequency of instillation, fecal preparation, and donor type. This variability should inform clinical, policy, and implementation decisions regarding FMT.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fmicb.2023.1286429
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Zhang, X., Luo, X., Liang, T.G., Yue, P., Li, M., Liu, K., Zhu, D., Huang, C., Shi, Q., Yang, L., Xia, Z., Zhao, J., Ma, Z., Li, J., Leung, J.W., Lin, Y., Yuan, J., Meng, W., Li, X., & Chen, Y. (2023). The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review. <em>Frontiers in Microbiology</em>. https://doi.org/10.3389/fmicb.2023.1286429
Vancouver
Zhang X, Luo X, Liang TG, Yue P, Li M, Liu K, et al. The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review. Frontiers in Microbiology. 2023. doi:10.3389/fmicb.2023.1286429.
BibTeX
@article{xianzhuo2023Thegut,
title = {The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review},
author = {Xianzhuo Zhang and Xufei Luo and Tian Gang Liang and Ping Yue and Mengyao Li and Kefeng Liu and Daoming Zhu and Chongfei Huang and Qianling Shi and Liping Yang and Zhili Xia and Jinyu Zhao and Zelong Ma and Jianlong Li and Joseph W. Leung and Yanyan Lin and Jinqiu Yuan and Wenbo Meng and Xun� Li and Yaolong Chen},
journal = {Frontiers in Microbiology},
year = {2023},
doi = {10.3389/fmicb.2023.1286429},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Medicine 2022
Open access · CC-BY
Gut Dysbiosis and Kidney Diseases
Frontiers in Endocrinology 2026
Open access · CC-BY
Gut microbiome dysbiosis in PCOS: from pathogenesis to microbiome-targeted therapies
Experientia supplementum 2018
Citation only
Microbiome and Gut Dysbiosis
Paediatrica Indonesiana 2025
Open access · CC-BY
Gut dysbiosis as a risk factor of neonatal sepsis among preterm infants
Journal of Clinical Medicine 2021
Open access · CC-BY
The Association between Early-Life Gut Microbiota and Long-Term Health and Diseases
Frontiers in aging neuroscience
Open access · OA